BACKGROUND: Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown. METHODS: DBS for TFV-DP were collected up to 3 times over 48 weeks in persons living with HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline TFV-DP was compared using t-tests or analyses of variance; generalized estimating equations were used to estimate the adjusted odds ratio (aOR) of viral suppression (<20 copies/mL) based on the TFV-DP concentration at the study visit. RESULTS: We analyzed 1199 DBS from 532 participants (76 female; 101 Black, 101 Hispanic). Among the virologically-suppressed participants at baseline (n = 347), TFV-DP was lower in Blacks (geometric mean 1453, 95% confidence interval [CI] 1291-1635) vs Whites (1793, 95% CI 1678-1916; P = .002) and Hispanics (1760, 95% CI 1563-1982; P = .025); in non-boosted (1610, 95% CI 1505-1723) vs. boosted (1888, 95% CI 1749-2037; P = .002) regimens; and in non-nucleoside reverse transcription inhibitor-based (1563, 95% CI 1432-1707) vs. boosted protease inhibitor-based (1890, 95% CI 1704-2095; P = .006) and multiclass-based (1927, 95% CI 1650-2252; P = .022) regimens. The aOR of virologic suppression, after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4+ T-cell count, antiretroviral drug class and duration of therapy, was 73.5 (95% CI 25.7-210.5; P < .0001) for a TFV-DP concentration ≥1850 fmol/punch compared to <350 fmol/punch. CONCLUSIONS: TFV-DP in DBS is strongly associated with virologic suppression in PLWH on TDF-based therapy and is associated with certain participant characteristics. Further research is required to evaluate this drug adherence and exposure measure in clinical practice. CLINICAL TRIALS REGISTRATION: NCT02012621.
BACKGROUND: Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown. METHODS:DBS for TFV-DP were collected up to 3 times over 48 weeks in persons living with HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline TFV-DP was compared using t-tests or analyses of variance; generalized estimating equations were used to estimate the adjusted odds ratio (aOR) of viral suppression (<20 copies/mL) based on the TFV-DP concentration at the study visit. RESULTS: We analyzed 1199 DBS from 532 participants (76 female; 101 Black, 101 Hispanic). Among the virologically-suppressed participants at baseline (n = 347), TFV-DP was lower in Blacks (geometric mean 1453, 95% confidence interval [CI] 1291-1635) vs Whites (1793, 95% CI 1678-1916; P = .002) and Hispanics (1760, 95% CI 1563-1982; P = .025); in non-boosted (1610, 95% CI 1505-1723) vs. boosted (1888, 95% CI 1749-2037; P = .002) regimens; and in non-nucleoside reverse transcription inhibitor-based (1563, 95% CI 1432-1707) vs. boosted protease inhibitor-based (1890, 95% CI 1704-2095; P = .006) and multiclass-based (1927, 95% CI 1650-2252; P = .022) regimens. The aOR of virologic suppression, after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4+ T-cell count, antiretroviral drug class and duration of therapy, was 73.5 (95% CI 25.7-210.5; P < .0001) for a TFV-DP concentration ≥1850 fmol/punch compared to <350 fmol/punch. CONCLUSIONS:TFV-DP in DBS is strongly associated with virologic suppression in PLWH on TDF-based therapy and is associated with certain participant characteristics. Further research is required to evaluate this drug adherence and exposure measure in clinical practice. CLINICAL TRIALS REGISTRATION: NCT02012621.
Authors: K Rivet Amico; William A Fisher; Deborah H Cornman; Paul A Shuper; Caroline G Redding; Deborah J Konkle-Parker; William Barta; Jeffrey D Fisher Journal: J Acquir Immune Defic Syndr Date: 2006-08-01 Impact factor: 3.731
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Jean B Nachega; Vincent C Marconi; Gert U van Zyl; Edward M Gardner; Wolfgang Preiser; Steven Y Hong; Edward J Mills; Robert Gross Journal: Infect Disord Drug Targets Date: 2011-04
Authors: Adrian S Ray; Tomas Cihlar; Kelly L Robinson; Leah Tong; Jennifer E Vela; Michael D Fuller; Lani M Wieman; Eugene J Eisenberg; Gerry R Rhodes Journal: Antimicrob Agents Chemother Date: 2006-10 Impact factor: 5.191
Authors: Albert Y Liu; Stephanie E Cohen; Eric Vittinghoff; Peter L Anderson; Susanne Doblecki-Lewis; Oliver Bacon; Wairimu Chege; Brian S Postle; Tim Matheson; K Rivet Amico; Teri Liegler; M Keith Rawlings; Nikole Trainor; Robert Wilder Blue; Yannine Estrada; Megan E Coleman; Gabriel Cardenas; Daniel J Feaster; Robert Grant; Susan S Philip; Richard Elion; Susan Buchbinder; Michael A Kolber Journal: JAMA Intern Med Date: 2016-01 Impact factor: 21.873
Authors: Richard M W Hoetelmans; Kris Mariën; Martine De Pauw; Andrew Hill; Monika Peeters; Vanitha Sekar; Piet De Doncker; Brian Woodfall; Eric Lefebvre Journal: Br J Clin Pharmacol Date: 2007-07-04 Impact factor: 4.335
Authors: Ellen F Eaton; Ashutosh Tamhane; Thibaut Davy-Mendez; William C Mathews; Richard D Moore; Michael S Saag; Michael J Mugavero Journal: AIDS Date: 2018-01-28 Impact factor: 4.177
Authors: Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla Journal: J Infect Dis Date: 2019-07-19 Impact factor: 5.226
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Jose R Castillo-Mancilla; Ryan P Coyle; Stacey S Coleman; Mary Morrow; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson Journal: AIDS Res Hum Retroviruses Date: 2019-07-30 Impact factor: 2.205
Authors: Paul K Drain; Ashley R Bardon; Jane M Simoni; Tim R Cressey; Pete Anderson; Derin Sevenler; Ayokunle O Olanrewaju; Monica Gandhi; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2020-10 Impact factor: 5.071
Authors: Ryan P Coyle; Christopher D Schneck; Mary Morrow; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson; Jose R Castillo-Mancilla Journal: AIDS Behav Date: 2019-12
Authors: Kristina M Brooks; Jose R Castillo-Mancilla; Joshua Blum; Ryan Huntley; Samantha MaWhinney; Keisha Alexander; Becky Jo Kerr; Lucas Ellison; Lane R Bushman; Christine E MacBrayne; Peter L Anderson; Jennifer J Kiser Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: Ryan P Coyle; Mary Morrow; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla Journal: J Antimicrob Chemother Date: 2020-06-01 Impact factor: 5.790
Authors: Katherine Frasca; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Jia-Hua Zheng; Samantha Mawhinney; Peter L Anderson; Jose Castillo-Mancilla Journal: J Antimicrob Chemother Date: 2019-05-01 Impact factor: 5.790